Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study (ReDEFINe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02169882
Recruitment Status : Completed
First Posted : June 23, 2014
Last Update Posted : June 1, 2017
Sponsor:
Collaborators:
United States Agency for International Development (USAID)
Radboud University
Information provided by (Responsible Party):
Universitas Padjadjaran

Brief Summary:

Tuberculous meningitis (TBM) is the most severe form of tuberculosis infection with high mortality. Current treatment regimens are not based on clinical trials. Rifampicin is a key drug for TBM, but its penetration into the brain is limited, suggesting that a higher dose may be more effective.

There are several highly relevant, outstanding questions related to the appropriate dose of rifampicin for TBM, before a multicenter phase 3 trial can be performed. These are:

  1. Previous phase 2a randomized clinical trial (done in the same setting as this proposed study) suggests that high doses of intravenous rifampicin (600mg, circa 13 mg/mg) for TBM is safe and associated with a survival benefit in adults. Given that i.v. rifampicin is not readily available, this needs to be confirmed using an equivalent higher oral dose of rifampicin.
  2. Recent pharmacokinetic analysis of a continuation trial comparing 600 mg i.v. rifampicin with 750 mg and 900 mg oral rifampicin suggests that an even higher dose may be needed; but this has not been examined
  3. Based on those previous data, there is a need to explore a longer duration of high-dose rifampicin for a subsequent phase 3 randomized clinical trial; treatment response in the investigators previous trial suggest that the optimal duration may be > 14 days.
  4. There is a need to explore relevant treatment endpoints besides mortality including neurological, neuroradiological and inflammatory response.

Condition or disease Intervention/treatment Phase
Tuberculosis, Meningeal Drug: Placebo Drug: Rifampicin Drug: Other TB drugs Drug: Adjuvant dexamethasone Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Double Blinded Phase 2b Clinical Trial Comparing Standard Dose With Two Higher Doses of Rifampicin for Treatment of Adults With Tuberculous Meningitis
Actual Study Start Date : December 1, 2014
Actual Primary Completion Date : November 5, 2016
Actual Study Completion Date : May 5, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Rifampin

Arm Intervention/treatment
Active Comparator: Rifampicin 450 mg (standard dose)

Twenty patients will receive 1 tablet of 450 mg Rifampicin and 2 tablets of placebo once daily for 30 days.

Unconscious subjects will receive oral drugs via nasogastric tubes (NGT).

After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.

Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.

Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)

Drug: Placebo

Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.

Patients receiving 1350 mg rifampicin will not receive any placebo tablet.

With this arrangement, every subject will receive 3 tablets of study drugs.


Drug: Other TB drugs

Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.

Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)


Drug: Adjuvant dexamethasone
Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)

Experimental: Rifampicin 900 mg per oral

Twenty patients will receive 2 tablets of 450 mg Rifampicin and 1 tablet of placebo once daily for 30 days.

Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)

After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.

Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.

Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)

Drug: Placebo

Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.

Patients receiving 1350 mg rifampicin will not receive any placebo tablet.

With this arrangement, every subject will receive 3 tablets of study drugs.


Drug: Rifampicin

Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.

Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section.

Other Name: Rifampisin - Kimia Farma

Drug: Other TB drugs

Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.

Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)


Drug: Adjuvant dexamethasone
Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)

Experimental: Rifampicin 1350 mg per oral

Twenty patients will receive 3 tablets of 450 mg Rifampicin and 0 tablet of placebo once daily for 30 days.

Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)

After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.

Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.

Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)

Drug: Rifampicin

Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.

Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section.

Other Name: Rifampisin - Kimia Farma

Drug: Other TB drugs

Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.

Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)


Drug: Adjuvant dexamethasone
Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)




Primary Outcome Measures :
  1. Rifampicin concentrations in plasma and cerebrospinal fluid (CSF) [ Time Frame: Day 2 (+/- 1) after administration of study drugs ]
    The rifampicin concentrations in plasma are measured from blood samples that are obtained by intensive pharmacokinetic sampling at 6 sampling time points (h0, 1, 2, 4, 8, 12 post dose). CSF rifampicin concentration will be measured using CSF sample taken by means of lumbar puncture at hour 3-6 post dose at the same day of blood sampling.


Secondary Outcome Measures :
  1. Rifampicin concentrations in plasma and CSF at steady-state [ Time Frame: Day 10 (+/- 1) after starting treatment with study drugs ]
    The rifampicin concentrations in plasma are measured from blood samples that are obtained by intensive pharmacokinetic sampling at 6 sampling time points (h0, 1, 2, 4, 8, 12 post dose). CSF rifampicin concentration will be measured using CSF sample taken by means of lumbar puncture at hour 3-6 post dose at the same day of blood sampling.

  2. Grade 3 and 4 and serious adverse events [ Time Frame: Within 60 days ]
    Determined by measurement of liver function, hematology, gastrointestinal intolerance and hypersensitivity at days 3, 7, 10, 14, 30, 45, and 60

  3. Mortality [ Time Frame: 180 days ]
  4. Neurological response [ Time Frame: Within 60 days ]
    Neurological responses that show both improvement (e.g. time to resolution of comma, time to fever resolution) and worsening (time to development of neurological deficits) will be measured and recorded at days 3, 7, 30 and 60.

  5. Neuroradiological response [ Time Frame: 60 days ]
    Development of infarction or other complication of TBM will documented by performing and comparing brain MRIs that will be done within the first 5 day and 60 day (+/- 5 days) after randomization

  6. Resolution of blood and CSF inflammatory response [ Time Frame: 7 days ]
    Inflammatory response will be measured at day 0 and day 7

  7. Sensitivity of GeneXpert for diagnosing TBM [ Time Frame: Within 6 weeks ]
    Every CSF sample from patients who come with suspicion of TBM will be inoculated in GeneXpert cartridge and standard culture measures (MODS), and the result will be compared.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or Female, aged 15 years or above.
  2. Clinical suspicion of TBM and CSF/blood glucose ratio < 0.5.
  3. None or less than 3 days of anti-tuberculosis chemotherapy taken for the current infection.
  4. Patient or representative (if the patient is incapacitated) is willing and able to give informed consent for participation in the study.
  5. Willingness to allow storage of specimens.

Exclusion Criteria:

Patients may not enter the study if any of the following apply:

  1. Liver dysfunction (ALT > 5 times upper limit); kidney dysfunction (eGFR < 50 ml/min)
  2. Pregnancy or breastfeeding (negative urine pregnancy test for all females of child-bearing age).
  3. Confirmed cryptococcus meningitis (LFA), or confirmed bacterial meningitis (microscopy).
  4. Rapid clinical deterioration at time of presentation (e.g. signs of sepsis, decreasing consciousness or signs of cerebral oedema, or herniation)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02169882


Locations
Layout table for location information
Indonesia
Hasan Sadikin General Hospital
Bandung, Jawa Barat, Indonesia, 40161
Sponsors and Collaborators
Universitas Padjadjaran
United States Agency for International Development (USAID)
Radboud University
Investigators
Layout table for investigator information
Principal Investigator: Rovina Ruslami, M.D., PhD Faculty of Medicine Universitas Padjadjaran, Bandung, Indonesia

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Universitas Padjadjaran
ClinicalTrials.gov Identifier: NCT02169882     History of Changes
Other Study ID Numbers: TB-201406.01
PGA-2000003601 ( Other Identifier: PEER Health )
First Posted: June 23, 2014    Key Record Dates
Last Update Posted: June 1, 2017
Last Verified: December 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Universitas Padjadjaran:
Tuberculous meningitis
Rifampicin
Dose finding study
Pharmacokinetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Meningitis, Bacterial
Antibiotics, Antitubercular
Anti-Bacterial Agents
Tuberculosis
Tuberculosis, Meningeal
Meningitis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Central Nervous System Diseases
Nervous System Diseases
Central Nervous System Bacterial Infections
Tuberculosis, Central Nervous System
Central Nervous System Infections
Pyridoxine
Rifampin
Pyrazinamide
Ethambutol
Dexamethasone
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones